Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A N Nafziger

Showing results (1-10 of 52) with videos related to

Pageof 6
Sort By:
Clinical Pharmacokinetics|April 16, 1998
Physiological changes during the menstrual cycle and their effects on the pharmacokinetics and pharmacodynamics of drugsA D Kashuba, A N Nafziger
European Journal of Clinical Pharmacology|January 1, 1989
Sex-related differences in theophylline pharmacokineticsA N Nafziger, J S Bertino
Antimicrobial Agents and Chemotherapy|March 1, 1996
Pharmacokinetics of oral fleroxacin in male and premenopausal female volunteersJ S Bertino, A N Nafziger
Antimicrobial Agents and Chemotherapy|November 26, 1997
Effects of moderate-dose versus high-dose trimethoprim on serum creatinine and creatinine clearance and adverse reactionsO Naderer, A N Nafziger, J S Bertino
Antimicrobial Agents and Chemotherapy|December 31, 1998
Pharmacokinetics in serum and leukocyte exposures of oral azithromycin, 1,500 milligrams, given over a 3- or 5-day period in healthy subjectsG W Amsden, A N Nafziger, G Foulds
The Journal of Antimicrobial Chemotherapy|June 26, 1999
Lack of effect of dirithromycin on theophylline pharmacokinetics in healthy volunteersS A McConnell, A N Nafziger, G W Amsden
Pharmacogenetics|May 10, 2000
Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probesD S Streetman, J S Bertino, A N Nafziger
Antimicrobial Agents and Chemotherapy|July 14, 1998
Dosing of aminoglycosides to rapidly attain pharmacodynamic goals and hasten therapeutic response by using individualized pharmacokinetic monitoring of patients with pneumonia caused by gram-negative organismsA D Kashuba, J S Bertino, A N Nafziger
Antimicrobial Agents and Chemotherapy|May 1, 1997
Pharmacokinetics of gentamicin at traditional versus high doses: implications for once-daily aminoglycoside dosingD J Demczar, A N Nafziger, J S Bertino
Antimicrobial Agents and Chemotherapy|March 11, 1992
Variation in the pharmacokinetics of gentamicin and tobramycin in patients with pleural effusions and hypoalbuminemiaJ V Etzel, A N Nafziger, J S Bertino
Pageof 6

Showing results (1-10 of 52) with videos related to

Sort By:
Pageof 6
Clinical Pharmacokinetics|April 16, 1998
Physiological changes during the menstrual cycle and their effects on the pharmacokinetics and pharmacodynamics of drugsA D Kashuba, A N Nafziger
European Journal of Clinical Pharmacology|January 1, 1989
Sex-related differences in theophylline pharmacokineticsA N Nafziger, J S Bertino
Antimicrobial Agents and Chemotherapy|March 1, 1996
Pharmacokinetics of oral fleroxacin in male and premenopausal female volunteersJ S Bertino, A N Nafziger
Antimicrobial Agents and Chemotherapy|November 26, 1997
Effects of moderate-dose versus high-dose trimethoprim on serum creatinine and creatinine clearance and adverse reactionsO Naderer, A N Nafziger, J S Bertino
Antimicrobial Agents and Chemotherapy|December 31, 1998
Pharmacokinetics in serum and leukocyte exposures of oral azithromycin, 1,500 milligrams, given over a 3- or 5-day period in healthy subjectsG W Amsden, A N Nafziger, G Foulds
The Journal of Antimicrobial Chemotherapy|June 26, 1999
Lack of effect of dirithromycin on theophylline pharmacokinetics in healthy volunteersS A McConnell, A N Nafziger, G W Amsden
Pharmacogenetics|May 10, 2000
Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probesD S Streetman, J S Bertino, A N Nafziger
Antimicrobial Agents and Chemotherapy|July 14, 1998
Dosing of aminoglycosides to rapidly attain pharmacodynamic goals and hasten therapeutic response by using individualized pharmacokinetic monitoring of patients with pneumonia caused by gram-negative organismsA D Kashuba, J S Bertino, A N Nafziger
Antimicrobial Agents and Chemotherapy|May 1, 1997
Pharmacokinetics of gentamicin at traditional versus high doses: implications for once-daily aminoglycoside dosingD J Demczar, A N Nafziger, J S Bertino
Antimicrobial Agents and Chemotherapy|March 11, 1992
Variation in the pharmacokinetics of gentamicin and tobramycin in patients with pleural effusions and hypoalbuminemiaJ V Etzel, A N Nafziger, J S Bertino
Pageof 6